

Rita Nanda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/118709/publications.pdf>

Version: 2024-02-01

85
papers

9,779
citations

81743

39
h-index

62479

80
g-index

89
all docs

89
docs citations

89
times ranked

11941
citing authors

#	ARTICLE	IF	CITATIONS
1	The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2022, 31, 531-548.	1.9	16
2	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 345-355.	0.8	23
3	Abstract P1-08-21: Assessing the impact of treatment interruptions during neoadjuvant therapy in early stage breast cancer. Cancer Research, 2022, 82, P1-08-21-P1-08-21.	0.4	0
4	Abstract P5-13-34: A multi-modal biomarker of immunotherapy response. Cancer Research, 2022, 82, P5-13-34-P5-13-34.	0.4	0
5	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	2.3	8
6	Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Academic Radiology, 2022, 29, 1469-1479.	1.3	3
7	ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.. Journal of Clinical Oncology, 2022, 40, TPS1120-TPS1120.	0.8	24
8	Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1126-TPS1126.	0.8	2
9	Racial differences in interest and use of integrative medicine among patients with breast cancer.. Journal of Clinical Oncology, 2022, 40, 12101-12101.	0.8	0
10	A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS611-TPS611.	0.8	1
11	Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.. Journal of Clinical Oncology, 2022, 40, 591-591.	0.8	4
12	The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.. Journal of Clinical Oncology, 2022, 40, 514-514.	0.8	6
13	Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 1-15.	1.1	19
14	Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Research and Treatment, 2021, 185, 841-849.	1.1	25
15	Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.. Journal of Clinical Oncology, 2021, 39, TPS1111-TPS1111.	0.8	0
16	Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).. Journal of Clinical Oncology, 2021, 39, TPS1098-TPS1098.	0.8	2
17	Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2021, 39, 1011-1011.	0.8	9
18	Independent validation of simbiosys tumorscope to predict response to neoadjuvant chemotherapy (NACT) in early breast cancer (EBC).. Journal of Clinical Oncology, 2021, 39, 582-582.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2021, 39, TPS1102-TPS1102.	0.8	3
20	Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.. Journal of Clinical Oncology, 2021, 39, 508-508.	0.8	9
21	Validation of the RSCLin risk calculator using the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, 549-549.	0.8	0
22	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5510-5518.	3.2	23
23	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell, 2021, 39, 989-998.e5.	7.7	131
24	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3938-3958.	0.8	40
25	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nature Communications, 2021, 12, 4423.	5.8	111
26	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	0.8	76
27	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. JAMA Oncology, 2021, 7, 1654.	3.4	42
28	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Npj Breast Cancer, 2021, 7, 131.	2.3	13
29	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nature Communications, 2021, 12, 6428.	5.8	36
30	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 2111-2123.	3.2	91
31	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 821-827.	3.2	40
32	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. JAMA Oncology, 2020, 6, 1355.	3.4	119
33	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	0.8	276
34	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. JAMA Oncology, 2020, 6, 1410.	3.4	161
35	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive and/or Hormone Receptorâ€“Negative Breast Cancers in the I-SPY 2 Trial. Journal of Clinical Oncology, 2020, 38, 1059-1069.	0.8	69
36	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 676.	3.4	419

#	ARTICLE	IF	CITATIONS
37	Atezolizumab for the treatment of breast cancer. Expert Review of Anticancer Therapy, 2020, 20, 151-158.	1.1	60
38	Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research, 2020, 80, CT011-CT011.	0.4	18
39	Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. , 2020, , .		4
40	Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097411.	1.4	12
41	Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS1102-TPS1102.	0.8	7
42	KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	0.8	12
43	Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics Journal, 2019, 19, 528-537.	0.9	12
44	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. JAMA Oncology, 2019, 5, 74.	3.4	557
45	Immune Checkpoint Blockade for Breast Cancer. Cancer Treatment and Research, 2018, 173, 155-165.	0.2	69
46	Molecular Profiling and Targeted Therapy for Triple-Negative Breast Cancer. , 2018, , 117-140.		0
47	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Research and Treatment, 2018, 167, 731-740.	1.1	71
48	Immune Checkpoint Inhibitor Therapy in Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1259-1268.	2.3	32
49	Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2018, 36, 884-890.	0.8	365
50	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Research and Treatment, 2018, 171, 637-648.	1.1	40
51	Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer, 2018, 124, 3052-3065.	2.0	14
52	Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Npj Breast Cancer, 2018, 4, 26.	2.3	24
53	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clinical Cancer Research, 2017, 23, 4066-4076.	3.2	87
54	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. Journal of Clinical Oncology, 2017, 35, 1008-1008.	0.8	99

#	ARTICLE	IF	CITATIONS
55	Phase 2 study of pembrolizumab as first-line therapy for PD-L1 ⁺ positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1088-1088.	0.8	55
56	Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. <i>Journal of Clinical Oncology</i> , 2017, 35, 506-506.	0.8	160
57	Immunotherapy Approaches to Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 227-235.	0.5	0
58	A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. <i>SpringerPlus</i> , 2016, 5, 947.	1.2	29
59	Adaptive Randomization of Veliparib ⁺ Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.	13.9	467
60	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 11-22.	13.9	301
61	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2460-2467.	0.8	1,185
62	TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. <i>Clinical Cancer Research</i> , 2016, 22, 5706-5712.	3.2	30
63	Concepts and targets in triple-negative breast cancer: recent results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 351-359.	1.4	24
64	Early and Severe Radiation Esophagitis Associated With Concurrent Sirolimus. <i>Journal of Clinical Oncology</i> , 2016, 34, e73-e75.	0.8	2
65	Utility of patient-derived lymphoblastoid cell lines as an <i>in vivo</i> capecitabine sensitivity prediction model for breast cancer patients. <i>Oncotarget</i> , 2016, 7, 38359-38366.	0.8	4
66	Treatment of leptomeningeal carcinomatosis: Current challenges and future opportunities. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 632-637.	0.8	46
67	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. <i>Clinical Cancer Research</i> , 2015, 21, 2771-2779.	3.2	78
68	Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017. <i>Annals of Surgical Oncology</i> , 2015, 22, 75-81.	0.7	12
69	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2911-2915.	3.2	77
70	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 ⁺ Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	0.8	49
71	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2722-2729.	3.2	57
72	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	1.1	59

#	ARTICLE	IF	CITATIONS
73	A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 145-153.	1.1	48
74	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. <i>Cancer</i> , 2013, 119, 1776-1783.	2.0	166
75	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2 Overexpressing Breast Cancer: TBCRC 006. <i>Journal of Clinical Oncology</i> , 2013, 31, 1726-1731.	0.8	238
76	Targeting Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers. <i>Seminars in Oncology</i> , 2011, 38, 254-262.	0.8	19
77	Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4515-4521.	0.8	341
78	Estrogen receptor β , BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 113-120.	1.1	82
79	Advances in Breast Cancer: Pathways to Personalized Medicine. <i>Clinical Cancer Research</i> , 2008, 14, 7988-7999.	3.2	165
80	Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 111-116.	0.4	46
81	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. <i>Modern Pathology</i> , 2006, 19, 264-271.	2.9	932
82	The molecular portraits of breast tumors are conserved across microarray platforms. <i>BMC Genomics</i> , 2006, 7, 96.	1.2	1,169
83	A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies. <i>PLoS Medicine</i> , 2006, 3, e486.	3.9	228
84	BRCA1 Promoter Methylation in Sporadic Breast Cancer Is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy. <i>Cancer Research</i> , 2005, 65, 10692-10699.	0.4	170
85	Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1925.	3.8	219